Source:http://linkedlifedata.com/resource/pubmed/id/15797523
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2005-3-30
|
pubmed:abstractText |
A rapid, sensitive and specific method was developed and validated using liquid chromatography-tandem mass spectrometry (LC/MS/MS) for determination of gefitinib in human plasma and mouse plasma and tissue. Sample preparation involved a single protein precipitation step by the addition of 0.1 mL of plasma or a 200 mg/mL tissue homogenate diluted 1/10 in human plasma with 0.3 mL acetonitrile. Separation of the compounds of interest, including the internal standard (d8)-gefitinib, was achieved on a Waters X-Terra C18 (50 mm x 2.1 mm i.d., 3.5 microm) analytical column using a mobile phase consisting of acetonitrile-water (70:30, v/v) containing 0.1% formic acid and isocratic flow at 0.15 mL/min for 3 min. The analytes were monitored by tandem mass spectrometry with electrospray positive ionization. Linear calibration curves were generated over the range of 1-1000 ng/mL for the human plasma samples and 5-1000 ng/mL for mouse plasma and tissue samples with values for the coefficient of determination of > 0.99. The values for both within- and between-day precision and accuracy were well within the generally accepted criteria for analytical methods (< 15%). This method was subsequently used to measure concentrations of gefitinib in mice following administration of a single dose of 150 mg/kg intraperitoneally and in cancer patients receiving an oral daily dose of 250 mg.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1570-0232
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
5
|
pubmed:volume |
819
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
73-80
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:15797523-Animals,
pubmed-meshheading:15797523-Biliary Tract Neoplasms,
pubmed-meshheading:15797523-Chromatography, High Pressure Liquid,
pubmed-meshheading:15797523-Drug Stability,
pubmed-meshheading:15797523-Female,
pubmed-meshheading:15797523-Humans,
pubmed-meshheading:15797523-Liver,
pubmed-meshheading:15797523-Mass Spectrometry,
pubmed-meshheading:15797523-Mice,
pubmed-meshheading:15797523-Mice, Nude,
pubmed-meshheading:15797523-Neoplasm Transplantation,
pubmed-meshheading:15797523-Quinazolines,
pubmed-meshheading:15797523-Receptor, Epidermal Growth Factor,
pubmed-meshheading:15797523-Reproducibility of Results,
pubmed-meshheading:15797523-Sensitivity and Specificity,
pubmed-meshheading:15797523-Skin
|
pubmed:year |
2005
|
pubmed:articleTitle |
Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry.
|
pubmed:affiliation |
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Bunting-Blaustein Cancer Research Building, Room 1M86, 1650 Orleans Street, Baltimore, MD 21231-1000, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural,
Validation Studies
|